NIPT, or noninvasive prenatal testing, offers a way to screen for specific chromosomal conditions by analyzing fragments of placental DNA found in your blood, providing early insights without any physical risk to the pregnancy itself.
What it is
NIPT, also known as cell-free DNA screening, is a blood test that looks at tiny pieces of placental DNA circulating in your bloodstream. These fragments of DNA are often identical to the baby's DNA and can provide clues about certain chromosomal conditions. It's a screening tool, which means it identifies a higher chance of a condition, but it doesn't give a definitive diagnosis. For example, evidence suggests NIPT has a detection rate of >99% for Down syndrome (trisomy 21).
It's important to understand that NIPT is not a diagnostic test. If a screening suggests a higher chance of a condition, further diagnostic testing, such as CVS — Chorionic Villus Sampling or amniocentesis, would be recommended to confirm the results before any decisions are made. While the false positive rate is low, it is a real consideration, particularly for rarer conditions like trisomy 13 and sex chromosome abnormalities.
Regarding who is offered NIPT, guidelines can vary. In the United States, the American College of Obstetricians and Gynecologists (ACOG) recommends offering NIPT to all pregnant people, regardless of age. In contrast, the UK's National Health Service (NHS) typically offers NIPT through its public system to individuals identified as higher risk, though private testing is widely available. You get to decide what feels right for you and your family.
Beyond screening for chromosomal conditions, NIPT can also accurately determine fetal sex from 10 weeks, making it the earliest accurate method available. Some NIPT panels may also include screening for microdeletions, such as DiGeorge syndrome, though these typically have lower detection rates and a higher chance of false positives.
